Genethon, created by AFM-Telethon, has the mission to make innovative  gene therapy treatments available to patients affected with rare genetic diseases. To meet this challenge Genethon has assembled the technical and human resources needed to accelerate the medical application of scientific discoveries arising from fundamental research. Strong translational research programs engage multi-disciplinary teams and are supported by a first rate technological platform and cGMP facility

The pipeline of Genethon includes products currently in international clinical trials and at preclinical stages, for muscular dystrophies, immune deficiencies, blood, ocular and liver diseases. These products are developed either with Genethon as sponsor, or in partnership with private companies and academic institutions.

Plasmid Factory

PlasmidFactory GmbH & Co. KG is a biopharmaceutical company, founded in Bielefeld in 2000.

Today the company is formed by a team of biologists, chemists, engineers and technicians. PlasmidFactory is the leading contract manufacturer of plasmid and minicircle DNA.

We produce your plasmids and minicircles according to your requirements in modern laboratories with high quality standards.

We are focussing R&D activities on our core competences: Production, analysis and storage of plasmid DNA.

At present, we are working on the following research topics – in close co-operation with industrial and academic partners.

  • Development of non-viral vector systems free of resistence gene sequences (minicircle)
  • Research on long-term storage of plasmid DNA and parameters influencing the stability (e.g. plasmid size, DNA concentration, storage buffer)
  • Influence of freeze and thaw conditions on plasmid topology
  • DNA vaccine development for cat fibrosarcoma
  • Production of dimer or multimer plasmids (e.g. reporter gene vectors)
  • Application of capillary gel electrophoresis (CGE) 
  • Optimization of vectors for co-transfection, e.g. for production of viruses (AAV, LV) or antibodies
  • Optimization of lentiviral vector systems
  • Vector development for hepatitis vaccines
  • Clinical and pre-clinical research for non-viral vectors
  • Microfluidic channel for separating minicircle and miniplasmids.


Genetrix, constitutes a group of biotech companies that develop and commercialize innovative products in the following markets: - Tools to amplify, repair and sequence DNA, which are essential for the main Molecular Biology techniques used in the lab and playa key role in the up-and-coming Personalized Medicine field. - Cell therapy, based on adult stem cells,which has proved to have enormous potential to tackle diseases that currently do not have established therapeutic treatment, such as myocardial infarction, rheumatoid arthritis o Parkinson’s disease. The Genetrix Group structure has been designed to: Transform academic results into: - Innovative sanitary products and services - Molecular Biology tools with global market potential Focus on high value investments, with the support of relevant industrial and financial partners for every project.

Sigma Aldrich

A reliable, single-source research partner providing high-quality reagents, technologies and industry-leading service to the life science and high technology markets. Scientific knowledge, innovation, high quality products and reliable delivery that support consistent, predictable results and save researchers time, are our strenght. The Company operates in 35 countries and sales in 160 countries whose objective is to provide excellent service worldwide. Global solutions for research and manufacturing customers, with our brands : · Sigma® Life Science : kits and reagents including genomics, functional genomics, proteomics and cell biology. · Aldrich® Chemistry : organic and inorganic chemicals, building blocks, reagents, advanced materials and stable isotopes. · Fluka® Analytical : Chemicals and reagents for analytical, organic and biochemical and pharmaceutical research and industries. · Supelco® Analytical : Chromatography columns and related tools. · SAFC®: Customized services and manufacturing.


AFM (French Muscular Dystrophy Association) has a single objective: to defeat neuromuscular diseases, which are devastating muscle-wasting diseases. Created in 1958 by a group of patients and their families, and recognised as being of public utility in 1976, it has set itself two missions: curing neuromuscular diseases and reducing the disabilities they cause.


Universal Nanotaxi® for Vaccines, Antibodies and Gene Therapies
In-Cell-Art is a French biopharmaceutical firm founded by a research team including Jean-Marie Lehn, a Nobel laureate and is specialized in nanocarriers called Nanotaxi® for intracellular delivery of macromolecules such as DNA, RNA and protein for development of innovative drugs.


GenoSafe® is a full contract research and consulting organization which specializes in evaluating the quality, safety and efficacy of innovative biological products.

We meet our clients’ specific needs by performing custom studies in strict compliance with regulatory requirements.

GenoSafe is a Good Laboratory Practices (GLP) compliant facility .

GenoSafe is eligible for the CIR (research tax credit). Our clients may include the R&D Services performed at GenoSafe in their own research tax credit calculation.

cellular dynamics

Cellular Dynamics International, a FUJIFILM company, develops and manufactures biologically relevant human cells derived from induced pluripotent stem (iPS) cells. Our iCell® and donor-specific MyCell® Products are highly pure, highly reproducible, and available in industrial quantity to enable drug discovery, toxicity testing, stem cell banking, and cell therapy development.

Univercell Biosolutions

Human cell models: a breakthrough in clinical prediction and industrial productivity

As a pioneering biotech company, Univercell-Biosolutions has coupled the potential of human hiPS with cellular reprogramming and directed differentiation technologies. Together these innovations yield purified populations of specific human cell types (cardiomyocytes, endothelial cells, beta cells) for drug-discovery applications. Univercell-Biosolutions has developed Mesopure® to provide a pure (>99%) population of cardiovascular progenitors as well as a pure population of Nkx2.5+ cardiac populations and quiescent ventricular cardiomyocytes .

Univercell-Biosolutions works with clinicians, academics and industry leaders to develop next-generation homogeneous, mature, functional and differentiated human cells with physiological characteristics closely matching those of adult differentiated cells in vivo.

Univercell-Biosolutions’ goals are to accelerate the discovery of new therapeutics and to reduce the drug failure rate in clinical trials.